Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to assess the effect of gabapentin as compared to placebo on sleep, using subjective sleep measurements, in subjects with transient insomnia induced by a sleep phase advance.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Gabapentin 250 mg | Experimental |
| |
| Gabapentin 500 mg | Experimental |
| |
| Placebo | Placebo Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Gabapentin | Drug | Gabapentin 250 mg oral capsule 30 minutes prior to bedtime |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Subjective sleep latency | Hour +8 |
| Measure | Description | Time Frame |
|---|---|---|
| Subjective assessment of sleep refreshment | Hour +8 | |
| Subjective assessment of sleep quality | Hour +8 | |
| Karolinska Sleep Diary-Sleep (KSD) Quality Index |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pfizer CT.gov Call Center | Pfizer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Pfizer Investigational Site | Anaheim | California | 92801 | United States | ||
| Pfizer Investigational Site |
Not provided
| Label | URL |
|---|---|
| To obtain contact information for a study center near you, click here. | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Gabapentin |
| Drug |
Gabapentin 500 mg oral capsule 30 minutes prior to bedtime |
|
| Placebo | Drug | Matched placebo 30 minutes prior to bedtime |
|
| Hour +8 |
| KSD individual scores | Hour +8 |
| Digit Symbol Substitution Test | Hour +8 |
| Buschke Selective Reminding Test (immediate recall score, long term storage score, total number of intrusions, delayed recall score) | Hour +8 |
| Stanford Sleepiness Scale | Hour +13 |
| Vital signs | Hour +8 |
| Adverse events | Hour +13 |
| Subjective number of awakenings | Hour +8 |
| Subjective wake after sleep onset | Hour +8 |
| Subjective total sleep time | Hour +8 |
| San Diego |
| California |
| 92121 |
| United States |
| Pfizer Investigational Site | Orlando | Florida | 32809 | United States |
| Pfizer Investigational Site | Boise | Idaho | 83704 | United States |
| Pfizer Investigational Site | Mount Laurel | New Jersey | 08054 | United States |
| Pfizer Investigational Site | Cincinnati | Ohio | 45219 | United States |
| Pfizer Investigational Site | Spartanburg | South Carolina | 29307 | United States |
| Pfizer Investigational Site | Dallas | Texas | 75235 | United States |
| ID | Term |
|---|---|
| D007319 | Sleep Initiation and Maintenance Disorders |
| ID | Term |
|---|---|
| D020919 | Sleep Disorders, Intrinsic |
| D020920 | Dyssomnias |
| D012893 | Sleep Wake Disorders |
| D009422 | Nervous System Diseases |
| D001523 | Mental Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D000077206 | Gabapentin |
| ID | Term |
|---|---|
| D000588 | Amines |
| D009930 | Organic Chemicals |
| D005680 | gamma-Aminobutyric Acid |
| D000613 | Aminobutyrates |
| D002087 | Butyrates |
| D000144 | Acids, Acyclic |
| D002264 | Carboxylic Acids |
| D003509 | Cyclohexanecarboxylic Acids |
| D000146 | Acids, Carbocyclic |
| D003510 | Cyclohexanes |
| D003516 | Cycloparaffins |
| D006840 | Hydrocarbons, Alicyclic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D000596 | Amino Acids |
| D000602 | Amino Acids, Peptides, and Proteins |
Not provided
Not provided